Loading
Life sciences · Journal article
International Journal of Molecular Sciences · September 5, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review of keyhole limpet hemocyanin (KLH) that synthesizes knowledge on its molecular structure, immunological properties, and potential therapeutic applications across vaccine development, cancer immunotherapy, and other fields. The review describes KLH's immunogenic characteristics and discusses emerging translational strategies but does not present original clinical or experimental evidence of therapeutic efficacy.
Narrative review.
KLH is a large copper-containing glycoprotein from marine gastropod Megathura crenulata with complex quaternary structure and extensive glycosylation KLH induces robust humoral and cellular immune responses in mammals without significant toxicity KLH displays extraordinary diversity of N-linked glycans distinguishing it from mammalian glycoproteins
Therapeutic applications described as 'emerging' or 'potential'; no efficacy or safety metrics provided Review does not quantify immunogenicity, toxicity, or clinical benefit in any human population
The source did not state who this applies to in practice.
This is a narrative review synthesizing existing knowledge on KLH structure and immunological mechanisms; it raises questions about therapeutic potential but does not present original clinical trial data or definitive evidence of efficacy.
As stated by the source record.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Keyhole limpet hemocyanin (KLH) is a large copper-containing glycoprotein derived from the marine gastropod Megathura crenulata. Originally functioning as an oxygen transport molecule, KLH has gained considerable attention in biomedical research due to its exceptional immunogenic and immunostimulatory properties. Its complex quaternary structure, extensive glycosylation, and xenogeneic origin contribute to its ability to induce robust humoral and cellular immune responses in mammals without significant toxicity. These characteristics have established KLH as one of the most widely used carrier proteins in vaccine development and as a valuable model antigen for the investigation of adaptive immune responses. This review summarizes current knowledge on the biological origin, molecular structure, biosynthesis, and post-translational processing of KLH, with particular emphasis on its unique glycan architecture and its contribution to immunogenicity. Advances in glycomic and structural analyses have revealed an extraordinary diversity of N-linked glycans that distinguish KLH from mammalian glycoproteins and play a central role in immune recognition. The review further discusses methods for KLH isolation, purification, and characterization, as well as its application in experimental and clinical immunology as a standardized tool for assessing antigen-specific immune responses. In addition, the therapeutic and translational potential of KLH is examined across multiple biomedical fields. Particular attention is given to its use as a carrier protein in conjugate vaccines, its role in cancer immunotherapy, and its emerging applications in the development of vaccines and immunotherapeutic strategies targeting neurodegenerative diseases, atherosclerosis, and substance use disorders. Collectively, the available evidence highlights KLH as a unique marine-derived biomolecule that bridges glycobiology, immunology, and translational medicine, and continues to serve as an important platform for the development of next-generation immunotherapeutics and vaccine technologies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.